PDCD1 and posterior cortical atrophy: In addition to these findings, combination of anti-CD73 antibodies with anti-PD-1 or anti-CTLA-4 treatment resulted in a substantial enhancement of antitumor activity in the RM-1 syngeneic mouse PCa model 195.